T2 Biosystems (TTOO) said Monday it was starting a multi-year distribution agreement with Cardinal Health (CAH), which will exclusively sell its direct-from-blood diagnostics equipment for the rapid detection of sepsis-causing pathogens.
Among the devices included under the new agreements are T2 Biosystems' US Food and Drug Administration-authorized T2Dx Instrument, T2Bacteria Panel and the T2Candida Panel. Financial terms and other details of the new contract were not disclosed.
Price: 111.65, Change: -0.34, Percent Change: -0.30
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments